Cargando…

Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study

There is no consensus on a treatment strategy for spinal giant cell tumor of bone (GCTB) because of the difficulty in their treatment. Treatment options often include the use of the controversial denosumab, an antibody therapy aimed at tumor shrinkage, different curettage techniques, resection, or a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Kazuhiko, Nishimura, Shunji, Miyamoto, Hiroshi, Toriumi, Kensuke, Ikeda, Terumasa, Akagi, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371551/
https://www.ncbi.nlm.nih.gov/pubmed/35960103
http://dx.doi.org/10.1097/MD.0000000000029963
_version_ 1784767175566819328
author Hashimoto, Kazuhiko
Nishimura, Shunji
Miyamoto, Hiroshi
Toriumi, Kensuke
Ikeda, Terumasa
Akagi, Masao
author_facet Hashimoto, Kazuhiko
Nishimura, Shunji
Miyamoto, Hiroshi
Toriumi, Kensuke
Ikeda, Terumasa
Akagi, Masao
author_sort Hashimoto, Kazuhiko
collection PubMed
description There is no consensus on a treatment strategy for spinal giant cell tumor of bone (GCTB) because of the difficulty in their treatment. Treatment options often include the use of the controversial denosumab, an antibody therapy aimed at tumor shrinkage, different curettage techniques, resection, or a combination of these therapies. The current study aimed to identify treatment methods associated with favorable outcomes in patients with spinal GCTB. We retrospectively reviewed 5 patients with spinal GCTB, including patients with tumors of the sacrum, treated at our hospital between September 2011 and November 2020. Two men and 3 women were included in the study. The median follow-up period was 74 months (range: 14–108 months). We surveyed the tumor site, treatment method, denosumab use, and outcomes. The median age was 17 years (range: 17–42 years). There were 2 cases of sacral GCTB and 1 case each of lumbar, cervical, and thoracic vertebral GCTB. The comorbidities observed included hepatitis, malignant lymphoma, atopic dermatitis, and asthma. The treatment method included zoledronic acid after embolization and denosumab, denosumab only, curettage and posterior fusion, and curettage resection after embolization and anterior and posterior fusion. Denosumab was used in all cases. Three patients were continuously disease-free, 1 patient with no evidence of disease, and 1 patient alive with disease. Aggressive treatment, especially surgical treatment, may lead to good results in spinal GCTB.
format Online
Article
Text
id pubmed-9371551
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93715512022-08-16 Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study Hashimoto, Kazuhiko Nishimura, Shunji Miyamoto, Hiroshi Toriumi, Kensuke Ikeda, Terumasa Akagi, Masao Medicine (Baltimore) Research Article There is no consensus on a treatment strategy for spinal giant cell tumor of bone (GCTB) because of the difficulty in their treatment. Treatment options often include the use of the controversial denosumab, an antibody therapy aimed at tumor shrinkage, different curettage techniques, resection, or a combination of these therapies. The current study aimed to identify treatment methods associated with favorable outcomes in patients with spinal GCTB. We retrospectively reviewed 5 patients with spinal GCTB, including patients with tumors of the sacrum, treated at our hospital between September 2011 and November 2020. Two men and 3 women were included in the study. The median follow-up period was 74 months (range: 14–108 months). We surveyed the tumor site, treatment method, denosumab use, and outcomes. The median age was 17 years (range: 17–42 years). There were 2 cases of sacral GCTB and 1 case each of lumbar, cervical, and thoracic vertebral GCTB. The comorbidities observed included hepatitis, malignant lymphoma, atopic dermatitis, and asthma. The treatment method included zoledronic acid after embolization and denosumab, denosumab only, curettage and posterior fusion, and curettage resection after embolization and anterior and posterior fusion. Denosumab was used in all cases. Three patients were continuously disease-free, 1 patient with no evidence of disease, and 1 patient alive with disease. Aggressive treatment, especially surgical treatment, may lead to good results in spinal GCTB. Lippincott Williams & Wilkins 2022-08-12 /pmc/articles/PMC9371551/ /pubmed/35960103 http://dx.doi.org/10.1097/MD.0000000000029963 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Hashimoto, Kazuhiko
Nishimura, Shunji
Miyamoto, Hiroshi
Toriumi, Kensuke
Ikeda, Terumasa
Akagi, Masao
Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study
title Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study
title_full Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study
title_fullStr Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study
title_full_unstemmed Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study
title_short Comprehensive treatment outcomes of giant cell tumor of the spine: A retrospective study
title_sort comprehensive treatment outcomes of giant cell tumor of the spine: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9371551/
https://www.ncbi.nlm.nih.gov/pubmed/35960103
http://dx.doi.org/10.1097/MD.0000000000029963
work_keys_str_mv AT hashimotokazuhiko comprehensivetreatmentoutcomesofgiantcelltumorofthespinearetrospectivestudy
AT nishimurashunji comprehensivetreatmentoutcomesofgiantcelltumorofthespinearetrospectivestudy
AT miyamotohiroshi comprehensivetreatmentoutcomesofgiantcelltumorofthespinearetrospectivestudy
AT toriumikensuke comprehensivetreatmentoutcomesofgiantcelltumorofthespinearetrospectivestudy
AT ikedaterumasa comprehensivetreatmentoutcomesofgiantcelltumorofthespinearetrospectivestudy
AT akagimasao comprehensivetreatmentoutcomesofgiantcelltumorofthespinearetrospectivestudy